First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate |
| |
| Authors: | Romney M. Humphries Shangxin Yang Peera Hemarajata Kevin W. Ward Janet A. Hindler Shelley A. Miller Aric Gregson |
| |
| Affiliation: | aDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA;bDepartment of Medicine, Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, California, USA |
| |
| Abstract: | Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 μg/ml) from a patient with no prior treatment with ceftazidime-avibactam. |
| |
| Keywords: | |
|
|
